Medicine and Diagnostic Access

Risks & contraindications

Comparisons

Other

Highlighted claims

• Insulin was less available in public-sector primary care in FCVs than in non-FCVs. — Inequities in diabetes prevention and control in fragile, conflict-affected and vulnerable settings: a mixed-methods study from the WHO Eastern Mediterranean Region
• Public HbA1C testing availability was much lower in FCVs than in non-FCVs. — Inequities in diabetes prevention and control in fragile, conflict-affected and vulnerable settings: a mixed-methods study from the WHO Eastern Mediterranean Region
• Advanced monitoring and complication-screening technologies were less available in FCV public-sector facilities. — Inequities in diabetes prevention and control in fragile, conflict-affected and vulnerable settings: a mixed-methods study from the WHO Eastern Mediterranean Region
• Metformin availability was high in both FCV and non-FCV country groups. — Inequities in diabetes prevention and control in fragile, conflict-affected and vulnerable settings: a mixed-methods study from the WHO Eastern Mediterranean Region
• Medication cost and supply were persistent barriers across the region, with FCVs facing the greatest challenges in insulin and medicine availability. — Inequities in diabetes prevention and control in fragile, conflict-affected and vulnerable settings: a mixed-methods study from the WHO Eastern Mediterranean Region
• Recommended supply actions included reviewing essential medicines, strengthening forecasting and procurement, improving supply chains and storage, and expanding local manufacturing capacity. — Inequities in diabetes prevention and control in fragile, conflict-affected and vulnerable settings: a mixed-methods study from the WHO Eastern Mediterranean Region